Cancer Research

Delaying second Pfizer-BioNTech dose could reduce cancer patients’ immunity

17 March 2021

More than half of cancer patients receiving a single dose of the Pfizer COVID-19 vaccine may be left with little protection against the virus, according to a new preprint from researchers at the Francis Crick Institute and King’s College London. Data from the world’s first reported trial to examine the level of immune protection after […]

Bicara Therapeutics launches biologics for cancer immunotherapy

16 March 2021

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumour microenvironment, launched with a US$40 million investment from Biocon. The financing will be used to advance a pipeline of first-in-class bifunctional antibodies developed by a global team, including a biologics engineering team in Bangalore, […]

Immodulon presents on clinical biomarker strategies

15 March 2021

Immodulon, the immuno-oncology company, will present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event taking place virtually 24-25 March 2021. The presentation, titled ‘Clinical Biomarker Strategy with a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget’, will be presented at 12:45 CET, March 25, 2021, by its Chief Scientific Officer, […]

Avacta enters diagnostic licensing deal with Biokit

10 March 2021

Avacta, developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has announced a licensing agreement with Biokit, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product. Biokit has experience in research, development and manufacturing of assays and biomaterial solutions for IVD use. Under the terms of the agreement […]

New study able to detect BRCA1 breast cells before they turn cancerous

10 March 2021

The earliest changes that occur in seemingly healthy breast tissue before tumours appear may have been found by researchers, suggests a new study published in Nature Communications. The study in mice, funded by Cancer Research UK, showed that before becoming cancerous, breast cells with the BRCA1 gene mutation undergo changes similar to those normally seen in […]

Pathios Therapeutics boosted with Innovate UK funding

9 March 2021

Pathios, a biotech company focused on the development of first-in-class therapies for cancer, announced that it has been awarded £350K in the form of a Smart Grant from Innovate UK. The UK government innovation agency’s money will accelerate Pathios’ cancer immunotherapy programme which targets the innate immune checkpoint, GPR65. Pathios will collaborate on this project […]

Vivan Therapeutics joins global Repositive Cancer Model network

4 March 2021

Repositive has announced that UK-based personalised therapeutics company Vivan Therapeutics will join its network of cancer model partners. Vivan Therapeutics is a personalised therapeutics company that engineers drosophila ‘avatar’ models for cancer research and development. Its technology engineers the genetic complexity of a cancer patient’s unique tumour network (up to 20 mutations or alterations) into […]

Avacta announces Phase I Clinical Trial Authorisation (CTA) for AVA6000

18 February 2021

Avacta, the developer of Affimer biotherapeutics and reagents, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a Phase I study of its lead pre|CISION pro-drug, AVA6000 pro-doxorubicin. In AVA6000, doxorubicin has been modified with Avacta’s pre|CISION chemistry, which renders the modified […]

Samsung Biologics obtains cancer immunotherapy IND approval from FDA

12 February 2021

Samsung Biologics has obtained Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). […]

4D pharma collaboration with Merck and Pfizer for urothelial carcinoma

8 February 2021

4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial […]

« Previous
Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free